Every 8-K that Puma Biotechnology Inc (PBYI) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow PBYI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PBYI filings page.
Puma Biotechnology reported results for the quarter ended June 30, 2026 and raised its 2026 revenue and net income guidance, citing increased demand for NERLYNX. Total revenue for the quarter was $56.5 million, including NERLYNX net product revenue of $53.6 million, up from $52.4 million and $49.2 million in the prior-year quarter. GAAP net income rose to $8.2 million, or $0.16 per basic and diluted share, from $5.9 million, while non-GAAP adjusted net income increased to $10.1 million.
For the first six months of 2026, total revenue was $101.3 million and GAAP net income was $4.4 million, down from $8.8 million, as operating costs grew to support alisertib clinical programs; R&D expenses rose to $38.7 million from $29.3 million. Cash, cash equivalents and marketable securities were $93.9 million at June 30, 2026, and outstanding debt was reduced to zero after the final payment under the 2021 Note Purchase Agreement. The company now guides 2026 total revenue to $224–$231 million and net income to $17–$20 million, and highlights multiple upcoming milestones in its ALISCA alisertib Phase II trials in breast and small cell lung cancer.
Puma Biotechnology, Inc. reported the results of its annual shareholder meeting. Stockholders elected eight directors, with each nominee receiving more votes "For" than "Withheld." Alan H. Auerbach received 37,130,678 votes "For" and 785,624 "Withheld," while other nominees showed similar support levels.
Shareholders also voted on three additional proposals. One proposal drew 42,612,940 votes "For" and 1,328,476 "Against". Another received 29,326,673 votes "For" and 7,878,580 "Against." A further proposal received 18,234,150 votes "For" and 19,596,238 "Against," indicating it did not obtain majority support.
Puma Biotechnology reported first quarter 2026 revenue of $44.8 million, slightly below $46.0 million a year earlier, as NERLYNX® net product revenue eased to $42.0 million from $43.1 million. The company posted a GAAP net loss of $3.8 million, versus net income of $3.0 million in 2025, while non-GAAP adjusted net loss was $1.9 million.
Research and development spending rose to $19.8 million, driven mainly by higher clinical trial costs for alisertib. Cash, cash equivalents and marketable securities were $101.5 million at March 31, 2026, and total debt fell to $11.3 million before being fully repaid on May 4, 2026.
Puma raised its 2026 outlook, guiding to total revenue of $222–$229 million and net income of $16–$19 million, up from prior ranges of $214–$221 million and $10–$13 million. Second quarter 2026 guidance calls for total revenue of $52–$55 million and net income of $2–$4 million, reflecting expectations for continued NERLYNX demand and ongoing alisertib development.
Puma Biotechnology reported higher fourth quarter 2025 revenue but flat full-year sales, while remaining profitable for a third straight year. Q4 2025 total revenue was $75.5 million, up from $59.1 million, driven by NERLYNX product revenue of $59.9 million and royalty revenue of $15.6 million. GAAP net income for the quarter was $13.4 million, or $0.26 per diluted share, down from $19.3 million, largely reflecting valuation allowance effects.
For full year 2025, total revenue was $228.4 million versus $230.5 million in 2024, while GAAP net income inched up to $31.1 million, or $0.61 per diluted share. Non-GAAP adjusted net income was $38.1 million. Operating cash flow strengthened to $41.8 million, and total debt declined sharply to $22.5 million from $67.0 million, improving the balance sheet.
For 2026, Puma guides total revenue to $214–$221 million and GAAP net income of $10–$13 million, implying lower profit than 2025 as it invests in R&D. The company highlighted ongoing Phase II ALISCA™-Breast1 and ALISCA™-Lung1 trials, with multiple clinical data readouts expected in 2026 alongside continued commercialization of NERLYNX.
Puma Biotechnology (PBYI) reported that it issued a press release announcing financial results for the third quarter ended September 30, 2025. The press release is furnished as Exhibit 99.1 to this report.
The company states the information under Item 2.02 is being furnished, not filed under the Exchange Act and will not be incorporated by reference into other filings. Additional exhibits include Exhibit 104 (Cover Page Interactive Data File in inline XBRL).
Puma Biotechnology, Inc. (Nasdaq: PBYI) filed a Form 8-K announcing that its Board of Directors approved and adopted Fifth Amended and Restated Bylaws on June 19, 2025. The revisions align the company’s corporate governance documents with recent updates to Delaware corporate law and include conforming and ministerial edits. No changes to the company’s fiscal year, capital structure, or financial guidance were disclosed. The amended bylaws are filed as Exhibit 3.1 and incorporated by reference.